Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Non-interventional, Long-term, Multinational Cohort Safety Study of Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (hATTR-PN)

NCT04850105 is registered in ClinicalTrials.gov with Akcea Therapeutics as lead sponsor.

NCT NCT04850105
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04850105 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Non-interventional, Long-term, Multinational Cohort Safety Study of Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (hATTR-PN)
Lead sponsor
Akcea Therapeutics
Phase
Observational
Overall status
Active, not recruiting
Start date
September 21, 2021
Completion date
March 31, 2036
Enrollment
202 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary transthyretin amyloidosis with polyneuropthy